Communiqués Avicanna Inc.

Actions

AVCN

CA05368K1003

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 18:47:59 09/10/2026			Varia. 5j.	Varia. 1 janv.
0,1150 ^CAD	+9,52%		+15,00%	-48,89%

19/08	Avicanna clôture un placement privé de 500 000 $ CA auprès de l'investisseur pharmaceutique Michael Porter	MT
15/08	Avicanna Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

15/09	Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026	AQ
09/09	Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada	AQ
19/08	Avicanna Announces Closing of Strategic Non-Brokered Private Placement	AQ
17/08	Avicanna Reports Q2 2026 Financial Results	AQ
15/08	Avicanna Reports Q2 2026 Financial Results	AQ
16/07	Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio	AQ
30/06	Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer	AQ
15/06	Avicanna Announces Closing of Non-Brokered Private Placement	AQ
14/05	Avicanna Reports Q1 2026 Financial Statements	AQ
08/05	Avicanna Announces Results of Annual General and Special Meeting	AQ
02/05	Avicanna Announces Change in Board of Directors	AQ
28/04	Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update	AQ
21/04	Annual General and Special Meeting of Shareholders to be held May 7, 2026	AQ
20/04	Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics	AQ
06/04	Avicanna Announces Changes to its Board of Directors	AQ
01/04	Avicanna Reports Full Year 2025 Audited Financial Statements	AQ
26/03	Avicanna Subsidiary SMGH Completes First Commercial Export to Australia	AQ
16/03	Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial	AQ
30/01	Avicanna Announces Medical Cannabis Real World Evidence Results and Publication	AQ
23/12	Avicanna Announces Changes to its Board of Directors	AQ
19/12	Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update	AQ
19/11	Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform	AQ
14/11	Avicanna Reports Q3 2025	AQ
13/09/25	Avicanna Announces Change in CFO	AQ
03/09/25	Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland	AQ